Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels

Cancer Research

Volumn 70, Issue 12, 2010, Pages 4850-4858

  Zhao, Jie ^a   Cao, Yuchun ^a   Lei, Zhang ^a   Yang, Zhuoshun ^a   Zhang, Biao ^a   Huang, Bo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; CYCLOPHOSPHAMIDE; GLUTATHIONE; MICRORNA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ARTICLE; ATTENUATION; CD4+ CD25+ T LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; DRUG DETOXIFICATION; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, NORTHERN; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; CYCLOPHOSPHAMIDE; FORKHEAD TRANSCRIPTION FACTORS; GLUTATHIONE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY;

EID: 77953730756     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0283     Document Type: Article

References (43)

1. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
2. Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 2007;7: 305-10.
3. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
4. Bonertz A, Weitz J, Pietsch DH, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009;119: 3311-21.
5. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009; 125:1640-8.
6. + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6301-11.
7. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405. (Pubitemid 44715110)
8. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008;28:109-26. (Pubitemid 351507425)
9. + T lymphocytes. Clin Exp Immunol 2007;150:523-30.
10. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
11. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997;56:481-7.
12. + suppressor T-cells. Cancer Res 1989;49:1649-54.
13. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 1987; 47:3317-21.
14. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
15. + T regulatory cell function implicated in enhanced immune response by low dose cyclophosphamide. Blood 2005;105:2862-8.
16. Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009;69:4309-18.
17. Castano AP, Mroz P, Wu MX, Hamblin MR. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci U S A 2008;105:5495-500.
18. Daenen LG, Shaked Y, Man S, et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009;8:2872-81.
19. Rooney PH, Telfer C, McFadyen MC, Melvin WT, Murray GI. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets 2004;4:257-65.
20. Gamcsik MP, Dolan ME, Andersson BS, Murray D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des 1999;5:587-605.
21. Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994;54: 6215-20.
22. Anderson ME. Glutathione and glutathione delivery compounds. Adv Pharmacol 1997;38:65-78.
23. Huang B, Zhao J, Lei Z, et al. miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep 2009;10:180-5.
24. Bopp T, Becker C, Klein M, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007;204:1303-10.
25. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32.
26. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65. (Pubitemid 46919862)
27. Alam MS, Kurtz CC, Rowlett RM, et al. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis 2009;199:494-504.
28. Chen W, Jin W, Hardegen N, et al.Conversionof peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86.
29. + regulatory T cells by retinoic acid. J Immunol 2009;183:4119-26.
30. Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 2003;64:785-95.
31. Corriden R, Insel PA, Junger WG. A novel method using fluorescence microscopy for real-time assessment of ATP release from individual cells. Am J Physiol Cell Physiol 2007;293:C1420-5. (Pubitemid 47556749)
32. Schenk U, Westendorf AM, Radaelli E, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal 2008;1:ra6.
33. Budagian V, Bulanova E, Brovko L, et al. Signaling through P2X7 receptor in human T cells involves p56lck, MAP kinases, and transcription factors AP-1 and NF-κB. J Biol Chem 2003;278:1549-60. (Pubitemid 36801383)
34. Yip L, Woehrle T, Corriden R, et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J 2009;23: 1685-93.
35. Aggarwal S, Tsuruo T, Gupta S. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans. J Clin Immunol 1997;17:448-54. (Pubitemid 28008102)
36. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58. (Pubitemid 37328807)
37. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001;21:778-96.
38. + content strictly depends on ATP concentration in isolated liver cells. FEBS Lett 1997; 410:329-32.
39. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen specific immune responses to cancer vaccines. Blood 2008;112:610-8.
40. Powell DJ, Jr., Attia P, Ghetie V, Schindler J, Vitetta ES, Rosenberg SA. Partial reduction of human FoxP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother 2008;31:189-98.
41. Allan SE, Broady R, Gregori S, et al. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 2008;223:391-421. (Pubitemid 351986179)
42. Nizar S, Copier J, Meyer B, et al. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009;100:1697-703.
43. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009;1174: 99-106.